scispace - formally typeset
W

Wendy Bruening

Researcher at Fox Chase Cancer Center

Publications -  7
Citations -  823

Wendy Bruening is an academic researcher from Fox Chase Cancer Center. The author has contributed to research in topics: Kinase & Cell cycle. The author has an hindex of 7, co-authored 7 publications receiving 792 citations. Previous affiliations of Wendy Bruening include Montreal Neurological Institute and Hospital.

Papers
More filters
Journal ArticleDOI

Up-regulation of protein chaperones preserves viability of cells expressing toxic Cu/Zn-superoxide dismutase mutants associated with amyotrophic lateral sclerosis

TL;DR: Evidence is presented that mutations in the Cu/Zn‐superoxidedismutase (SOD‐1) gene underlie some familial cases of amytotrophic lateral sclerosis, a neurodegenerative disorder charactreized by loss of cortical, brainstem, and spinal motor nrurons, and that insufficiency of molecular chaperones may be directly involved in loss of motor neurons in this disease.
Journal ArticleDOI

Synucleins are expressed in the majority of breast and ovarian carcinomas and in preneoplastic lesions of the ovary.

TL;DR: Examination of a panel of breast and ovarian carcinomas for expression of α, β, and γ synucleins found that α synuclein has attracted considerable attention due to its involvement in neurodegenerative diseases.
Journal ArticleDOI

γ-Synuclein Promotes Cancer Cell Survival and Inhibits Stress- and Chemotherapy Drug-induced Apoptosis by Modulating MAPK Pathways *

TL;DR: Oncogenic activation of γ-synuclein contributes to the development of breast and ovarian cancer by promoting tumor cell survival under adverse conditions and by providing resistance to certain chemotherapeutic drugs.
Journal ArticleDOI

Activation of stress-activated MAP protein kinases up-regulates expression of transgenes driven by the cytomegalovirus immediate/early promoter.

TL;DR: It is found that the same conditions that lead to activation of SAPK/JNKs and p38 kinases can also dramatically increase expression from the CMV promoter, which may complicate, if not invalidate, the interpretation of a wide range of experiments.
Journal Article

Expression of OVCA1, a Candidate Tumor Suppressor, Is Reduced in Tumors and Inhibits Growth of Ovarian Cancer Cells

TL;DR: Results suggest that slight alterations in the level of OVCA1, such as would occur after reduction of chromosome 17p13.13 to hemizygosity, may result in cell cycle deregulation and promote tumorigenesis.